Patents by Inventor Christian Von Törne
Christian Von Törne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10851427Abstract: The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer, said method comprising: (a) determining in a tumor sample from said patient the RNA expression levels of at least 2 of the following 9 genes: UBE2C, BIRC5, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP (b) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is indicative of a prognosis of said patient; and kits and systems for performing said method.Type: GrantFiled: January 17, 2020Date of Patent: December 1, 2020Assignee: MYRIAD INTERNATIONAL GMBHInventors: Mareike Dartmann, Inke Sabine Feder, Mathias Gehrmann, Guido Hennig, Karsten Weber, Christian Von Törne, Ralf Kronenwett, Christoph Petry
-
Publication number: 20200224281Abstract: The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer, said method comprising: (a) determining in a tumor sample from said patient the RNA expression levels of at least 2 of the following 9 genes: UBE2C, BIRC5, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP (b) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is indicative of a prognosis of said patient; and kits and systems for performing said method.Type: ApplicationFiled: January 17, 2020Publication date: July 16, 2020Applicant: MYRIAD INTERNATIONAL GMBHInventors: Mareike DARTMANN, Inke Sabine FEDER, Mathias GEHRMANN, Guido HENNIG, Karsten WEBER, Christian VON TÖRNE, Ralf KRONENWETT, Christoph PETRY
-
Patent number: 10577661Abstract: The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer, said method comprising: (a) determining in a tumor sample from said patient the RNA expression levels of at least 2 of the following 9 genes: UBE2C, BIRC5, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP (b) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is indicative of a prognosis of said patient; and kits and systems for performing said method.Type: GrantFiled: August 11, 2016Date of Patent: March 3, 2020Assignee: MYRIAD INTERNATIONAL GMBHInventors: Mareike Dartmann, Inke Sabine Feder, Mathias Gehrmann, Guido Hennig, Karsten Weber, Christian Von Törne, Ralf Kronenwett, Christoph Petry
-
Publication number: 20170067118Abstract: The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer, said method comprising: (a) determining in a tumor sample from said patient the RNA expression levels of at least 2 of the following 9 genes: UBE2C, BIRC5, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP (b) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is indicative of a prognosis of said patient; and kits and systems for performing said method.Type: ApplicationFiled: August 11, 2016Publication date: March 9, 2017Applicant: Sividon Diagnostics GmbHInventors: Mareike Dartmann, Inke Sabine Feder, Mathias Gehrmann, Guido Hennig, Karsten Weber, Christian Von Törne, Ralf Kronenwett, Christoph Petry
-
Publication number: 20130065786Abstract: The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer, said method comprising: (a) determining in a tumor sample from said patient the RNA expression levels of at least 2 of the following 9 genes: UBE2C, BIRC5, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP (b) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is indicative of a prognosis of said patient; and kits and systems for performing said method.Type: ApplicationFiled: March 29, 2011Publication date: March 14, 2013Applicant: Sividon Diagnostics GmbHInventors: Mareike Dartmann, Inke Sabine Feder, Mathias Gehrmann, Guido Hennig, Karsten Weber, Christian Von Törne, Ralf Kronenwett, Christoph Petry
-
Publication number: 20130040843Abstract: Methods for increasing multiplex level by externalization of a passive reference in polymerase chain reactions (PCR) are provided. An exemplary method comprises providing a first mastermix including a passive fluorescence dye in at least a first well of a plate; providing a second mastermix including an active fluorescence dye in at least a second well of the plate; wherein the passive fluorescence dye and the active fluorescence dye emit a same spectrum and an intensity of the spectrum is adapted to be measured; and wherein the first mastermix is devoid of an active fluorescence dye emitting the same spectrum and the second mastermix is devoid of the passive fluorescence dye emitting the same spectrum. Numerous other aspects are provided.Type: ApplicationFiled: February 4, 2011Publication date: February 14, 2013Applicant: Siemens Healthcare Diagnostics Inc.Inventors: Christian Von Töerne, Udo Stropp
-
Patent number: 8355874Abstract: The invention relates to a method for developing a biomarker for the prognosis of the result of a therapeutical treatment based on data obtained in clinical studies, data remaining unchanged by therapy being subdivided into diagnostic and genomic parameters and the marker being defined by a combination of parameters. The method according to the invention is characterized by specifying the maximum number of parameters for defining the marker and thus the maximum complexity of the system from the beginning and by carrying out the search for defining parameters by sequential combination of clinical parameters (=z parameters) and/or genomic parameters (=x parameters).Type: GrantFiled: December 11, 2006Date of Patent: January 15, 2013Assignee: Bayer Technology Services GmbHInventors: Andreas Schuppert, Rolf Burghaus, Christian Von Törne, Stephan Schwers, Udo Stropp, Harald Kallabis
-
Publication number: 20110172928Abstract: The present invention relates to methods for prediction of an outcome of neoplastic disease or cancer. More specifically, the present invention relates to a method for the prediction of breast cancer by determining in a biological sample from said patient an expression level of a plurality of genes selected from the group consisting of ACTG1, CA12, CALM2, CCND1, CHPT1, CLEC2B, CTSB, CXCL13, DCN, DHRS2, EIF4B, ERBB2, ESR1, FBXO28, GABRP, GAPDH, H2AFZ, IGFBP3, IGHG1, IGKC, KCTD3, KIAA0101, KRT17, MLPH, MMP1, NAT1, NEK2, NR2F2, OAZ1, PCNA, PDLIM5, PGR, PPIA, PRC1, RACGAP1, RPL37A, SOX4, TOP2A, UBE2C and VEGF.Type: ApplicationFiled: June 16, 2009Publication date: July 14, 2011Applicant: Sividon DiagnosticsInventors: Mathias Gehrmann, Udo Stropp, Karsten Weber, Christian Von Törne, Marcus Schmidt
-
Publication number: 20110166838Abstract: The invention relates to methods for predicting an outcome of cancer in a patient suffering from cancer, said patient having been previously diagnosed as node positive and treated with cytotoxic chemotherapy, said method comprising determining in a biological sample from said patient an expression level of a plurality of genes selected from the group consisting of ACTG1, CAl2, CALM2, CCND1, CHPT1, CLEC2B, CTSB, CXCL13, DCN, DHRS2, EIF4B, ERBB2, ESR1, FBXO28, GABRP, GAPDH, H2AFZ, IGFBP3, IGHG1, IGKC, KCTD3, KIAA0101, KRT17, MLPH, MMP1, NAT1, NEK2, NR2F2, OAZ1, PCNA, PDLIM5, PGR, PPIA, PRC1, RACGAP1, RPL37A, SOX4, TOP2A, UBE2C and VEGF; ABCB1, ABCG2, ADAM15, AKR1C1, AKR1C3, AKT1, BANF1, BCL2, BIRC5, BRMS1, CASP10, CCNE2, CENPJ, CHPT1, EGFR, CTTN, ERBB3, ERBB4, FBLN1, FIP1L1, FLT1, FLT4, FNTA, GATA3, GSTP1, Herstatin, IGF1R, IGHM, KDR, KIT, CKRT5, SLC39A6, MAPK3, MAPT, MKI67, MMP7, MTA1, FRAP1, MUC1, MYC, NCOA3, NFIB, OLFM1, TP53, PCNA, PI3K, PPERLD1, RAB31, RAD54B, RAF1, SCUBE2, STAU, TINF2, TMSL8, VGLL1, TRA@,Type: ApplicationFiled: June 16, 2009Publication date: July 7, 2011Applicant: Sividon DiagnosticsInventors: Mathias Gehrmann, Ralf Kronenwett, Udo Stropp, Christian Von Törne, Karsten Weber
-
Publication number: 20110166845Abstract: The invention relates to a method for the quality assessment of nucleic acid amplification reactions which is based on a mathematical approach for the quality assessment of complete nucleic acid amplification reactions and comprises the following steps: a) Carrying out an amplification reaction for at least one nucleic acid target molecule, b)Collecting time-related data reflecting the course of the amplification reaction, c) Fitting these time-related data with a growth model equation comprising at least one parameter, d) Obtaining, from said fitting process, at least one value for the at least one parameter.Type: ApplicationFiled: July 16, 2009Publication date: July 7, 2011Applicant: SIVIDON DIAGNOSTICS GMBHInventors: Christian Von Törne, Mareike Assink, Udo Stropp
-
Publication number: 20090311700Abstract: The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer in untreated breast cancer patients. More specific, the present invention relates to the prognosis of breast cancer based on measurements of the expression levels of marker genes in tumor samples of breast cancer patients. Marker genes are disclosed which allow for an accurate prognosis of breast cancer in patients having node negative, fast proliferating breast cancer.Type: ApplicationFiled: September 25, 2007Publication date: December 17, 2009Applicant: Siemens Healthcare Diagnositcs Inc.Inventors: Mathias Gehrmann, Christian von Törne
-
Publication number: 20090239223Abstract: The invention relates to methods and kits for the prediction of a likely outcome of chemotherapy in a cancer patient. More specifically, the invention relates to the prediction of tumour response to chemotherapy based on measurements of expression levels of a small set of marker genes. The set of marker genes is useful for the identification of breast cancer subtypes responsive to taxane based chemotherapy, such as e.g. a taxane-anthracycline-cyclophosphamide-based (e.g. Taxotere (docetaxel)-Adriamycin (doxorubicin)-cyclophosphamide, i.e. (TAC)-based) chemotherapy.Type: ApplicationFiled: July 6, 2007Publication date: September 24, 2009Applicant: SIEMENS HEALTHCARE DIAGNOSTICS INC.Inventors: Mathias Gehrmann, Christian Von Törne
-
Publication number: 20090222387Abstract: The present invention relates to methods and compositions for the diagnosis, prognosis, and prediction of breast cancer. More specifically, the invention relates to classification of breast cancer tissue samples based on measuring the expression of a set of marker genes. The set is useful for the identification of clinically important breast cancer subtypes. Methods are disclosed for prediction, diagnosis and prognosis of breast cancer.Type: ApplicationFiled: June 14, 2006Publication date: September 3, 2009Inventors: Mathias Gehrmann, Christian Von Törne
-
Publication number: 20090069196Abstract: Method for the prediction of the response to epirubicin/cyclophosphamide-based chemotherapy of a breast cancer in a patient, from a tumour sample of said patient, comprising steps of determining the expression level of a group of marker genes consisting of (i) a first marker gene selected from the group consisting of MLPH, SPDEF, and AKR7A3; and (ii) a pair of second marker genes selected from the group of pairs consisting of (H2BFS and UBE2S), (BGN and ZBTB16), (ZBTB16 and EMP1), (LGALS8 and UBE2S) and (OLFML2B and ZBTB16); and (iii) a third marker gene selected from the group consisting of CYBA, ACP5, a gene specifically binding to Affymetrix probe set ID 210915 x at, LCK, GSTM3; classifying said sample as belonging to one of several breast cancer response classes from the expression levels determined; predicting the response of said breast cancer in said patient to chemotherapy from previously known characteristic properties of tumours of said one of several breast cancer response classes.Type: ApplicationFiled: March 9, 2007Publication date: March 12, 2009Inventors: Mathias Gehrmann, Christian Von Toerne